SEARCH

SEARCH BY CITATION

References

  • 1
    Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003;139:82434.
  • 2
    DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397405.
  • 3
    Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:8139.
  • 4
    Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003;46:M916.
  • 5
    Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:157783.
  • 6
    NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:146376.
  • 7
    Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ et al. HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011;54:6972.
  • 8
    Davidson MB. Counterpoint: postprandial glucose levels are not a clinically important treatment target. Diabetes Care 2010;33:190810.
  • 9
    Ceriello A. Point: postprandial glucose levels are a clinically important treatment target. Diabetes Care 2010;33:19057.
  • 10
    Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002;106:12118.
  • 11
    Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:134954.
  • 12
    Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy M-A, Simonson DC et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695701.
  • 13
    Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:206772.
  • 14
    Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998;30:1469.
  • 15
    Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005;111:251824.
  • 16
    Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2002;101:224751.
  • 17
    Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:114550.
  • 18
    Ioannidis I, Tsoukala C, Panayotopoulou C, Skrapari I, Maglara E, Anastasopoulou Y et al. Effects of glibenclamide on postprandial coagulation activation. Nutr Metab Cardiovasc Dis 1999;9:2047.
  • 19
    Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003;41:101320.
  • 20
    Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:191924.
  • 21
    Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006;91:83742.
  • 22
    Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C et al. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 2011;34:2733.
  • 23
    Markela E, Stahlberg TH, Hemmila I. Europium-labelled recombinant protein G. A fast and sensitive universal immunoreagent for time-resolved immunofluorometry. J Immunol Methods 1993;161:16.
  • 24
    Andersen L, Jorgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 2000;33:62733.
  • 25
    Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003;26:32739.
  • 26
    Itaya K, Ui M. Colorimetric determination of free fatty acids in biological fluids. J Lipid Res 1965;6:1620.
  • 27
    Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996;39:46973.
  • 28
    Jilma B, Dallinger S, Hergovich N, Eichler HG, Richter V, Wagner OF. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules. J Clin Endocrinol Metab 2000;85:174851.
  • 29
    Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:203641.
  • 30
    Coppola L, Coppola A, Grassia A, Mastrolorenzo L, Lettieri B, De Lucia D et al. Acute hyperglycemia alters von Willebrand factor but not the fibrinolytic system in elderly subjects with normal or impaired glucose tolerance. Blood Coagul Fibrinolysis 2004;15:62935.
  • 31
    von Känel R, Nelesen RA, Le DT, Ziegler MG, Dimsdale JE. Decrease in the plasma von Willebrand factor concentration following glucose ingestion: the role of insulin sensitivity. Metabolism 2001;50:14526.
  • 32
    Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:3816.
  • 33
    Slama G, Elgrably F, Sola A, Mbemba J, Larger E. Postprandial glycaemia: a plea for the frequent use of delta postprandial glycaemia in the treatment of diabetic patients. Diabetes Metab 2006;32:18792.